Abstract
Purpose
Pixantrone is a synthetic aza-anthracenedione currently used in the treatment of non-Hodgkin’s lymphoma. The drug is firmly established as a poison of the nuclear enzyme topoisomerase II, however, pixantrone can also generate covalent drug-DNA adducts following activation by formaldehyde. While pixantrone-DNA adducts form proficiently in vitro, little evidence is presently at hand to indicate their existence within cells. The molecular nature of these lesions within cancer cells exposed to pixantrone and formaldehyde-releasing prodrugs was characterized along with the cellular responses to their formation.
Methods
In vitro crosslinking assays, [14C] scintillation counting analyses and alkaline comet assays were applied to characterize pixantrone-DNA adducts. Flow cytometry, cell growth inhibition and clonogenic assays were used to measure cancer cell kill and survival.
Results
Pixantrone-DNA adducts were not detectable in MCF-7 breast cancer cells exposed to [14C] pixantrone (10–40 µM) alone, however the addition of the formaldehyde-releasing prodrug AN9 yielded readily measurable levels of the lesion at ~ 1 adduct per 10 kb of genomic DNA. Co-administration with AN9 completely reversed topoisomerase II-associated DNA damage induction by pixantrone yet potentiated cell kill by the drug, suggesting that pixantrone-DNA adducts may promote a topoisomerase II-independent mechanism of cell death. Pixantrone-DNA adduct-forming treatments generally conferred mild synergism in multiple cell lines in various cell death and clonogenic assays, while pixantrone analogues either incapable or relatively defective in forming DNA adducts demonstrated antagonism when combined with AN9.
Conclusions
The features unique to pixantrone-DNA adducts may be leveraged to enhance cancer cell kill and may be used to guide the design of pixantrone analogues that generate adducts with more favorable anticancer properties.
Similar content being viewed by others
Availability of data and materials
Not applicable.
Code availability
Not applicable.
References
Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2016) Mitoxantrone, more than just another topoisomerase II poison. Med Res Rev 36(2):248–299. https://doi.org/10.1002/med.21364
Smith PJ, Morgan SA, Fox ME, Watson JV (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 40(9):2069–2078
Parker BS, Cullinane C, Phillips DR (1999) Formation of DNA adducts by formaldehyde-activated mitoxantrone. Nucleic Acids Res 27(14):2918–2923
Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR (2004) A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J Biol Chem 279(18):18814–18823. https://doi.org/10.1074/jbc.M400931200
Corbett TH, Griswold DP Jr, Roberts BJ, Schabel FM Jr (1981) Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol 6(2):161–168
Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP, Giuliani FC et al (1994) 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem 37(6):828–837
Pean E, Flores B, Hudson I, Sjoberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F (2013) The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin’s B cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 18(5):625–633. https://doi.org/10.1634/theoncologist.2013-0020
Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F (2007) Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 25(3):187–195. https://doi.org/10.1007/s10637-007-9037-8
Longo M, Della Torre P, Allievi C, Morisetti A, Al-Fayoumi S, Singer JW (2014) Tolerability and toxicological profile of pixantrone (Pixuvri(R)) in juvenile mice. Comparative study with doxorubicin. Reprod Toxicol 46:20–30. https://doi.org/10.1016/j.reprotox.2014.02.006
De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC et al (1995) Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 48(1):30–38
Zwelling LA, Mayes J, Altschuler E, Satitpunwaycha P, Tritton TR, Hacker MP (1993) Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol 46(2):265–271
Evison BJ, Mansour OC, Menta E, Phillips DR, Cutts SM (2007) Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 35(11):3581–3589. https://doi.org/10.1093/nar/gkm285
Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A (1991) Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer J Int Cancer 49(1):66–72
Rephaeli A, Entin-Meer M, Angel D, Tarasenko N, Gruss-Fischer T, Bruachman I, Phillips DR, Cutts SM, Haas-Kogan D, Nudelman A (2006) The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs 24(5):383–392. https://doi.org/10.1007/s10637-006-6213-1
Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA (2005) Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4(12):1952–1961. https://doi.org/10.1158/1535-7163.Mct-05-0087
Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM (2010) New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. J Med Chem 53(19):6851–6866. https://doi.org/10.1021/jm901894c
Salti GI, Das Gupta TK, Constantinou AI (2000) A novel use for the comet assay: detection of topoisomerase II inhibitors. Anticancer Res 20(5A):3189–3193
Olive PL (1989) Cell proliferation as a requirement for development of the contact effect in Chinese hamster V79 spheroids. Radiat Res 117(1):79–92
Olive PL, Banath JP, Durand RE (1990) Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the “comet” assay. Radiat Res 122(1):86–94
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4
Harker WG, Slade DL, Drake FH, Parr RL (1991) Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30(41):9953–9961
Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochem Pharmacol 82(11):1604–1618. https://doi.org/10.1016/j.bcp.2011.08.013
Valiathan C, McFaline JL, Samson LD (2012) A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects. DNA Repair 11(1):92–98. https://doi.org/10.1016/j.dnarep.2011.11.002
Evison BJ, Chiu F, Pezzoni G, Phillips DR, Cutts SM (2008) Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 74(1):184–194. https://doi.org/10.1124/mol.108.045625
Thorndike J, Beck WS (1977) Production of formaldehyde from N5-methyltetrahydrofolate by normal and leukemic leukocytes. Can Res 37(4):1125–1132
Liu J, Liu FY, Tong ZQ, Li ZH, Chen W, Luo WH, Li H, Luo HJ, Tang Y, Tang JM, Cai J, Liao FF, Wan Y (2013) Lysine-specific demethylase 1 in breast cancer cells contributes to the production of endogenous formaldehyde in the metastatic bone cancer pain model of rats. PLoS ONE 8(3):e58957. https://doi.org/10.1371/journal.pone.0058957
DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW (2006) Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 57(3):335–342. https://doi.org/10.1007/s00280-005-0060-1
Dhareshwar SS, Stella VJ (2008) Your prodrug releases formaldehyde: should you be concerned? No! J Pharm Sci 97(10):4184–4193. https://doi.org/10.1002/jps.21319
Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9(5):338–350. https://doi.org/10.1038/nrc2607
Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Can Res 66(9):4863–4871. https://doi.org/10.1158/0008-5472.CAN-05-3410
Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR (2008) Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res 36(16):e100. https://doi.org/10.1093/nar/gkn439
Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45(3):381–386. https://doi.org/10.1016/j.lungcan.2004.03.002
Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H (2021) Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B 11(9):2726–2737. https://doi.org/10.1016/j.apsb.2021.01.004
Konda SK, Kelso C, Medan J, Sleebs BE, Phillips DR, Cutts SM, Collins JG (2016) Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts. Org Biomol Chem 14(43):10217–10221. https://doi.org/10.1039/c6ob02100j
Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG (2016) Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA. Org Biomol Chem 14(20):4728–4738. https://doi.org/10.1039/c6ob00561f
Acknowledgements
This work was supported by the National Health and Medical Research Council (S.C and D.P) and the CASS Foundation (S.C and B.E).
Funding
This work was supported by the National Health and Medical Research Council (S.C and D.P) and the CASS Foundation (S.C and B.E).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
B.E. is an employee of Nyrada Inc. and declares no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mansour, O.C., Nudelman, A., Rephaeli, A. et al. An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells. Cancer Chemother Pharmacol 89, 773–784 (2022). https://doi.org/10.1007/s00280-022-04435-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-022-04435-1